<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647528</url>
  </required_header>
  <id_info>
    <org_study_id>Chromogenex Acne</org_study_id>
    <nct_id>NCT02647528</nct_id>
  </id_info>
  <brief_title>A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris</brief_title>
  <acronym>Chromogenix</acronym>
  <official_title>A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadick Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadick Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser&#xD;
      (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding withdrawn&#xD;
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Acne Assessment Scoring</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm receive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm do not receive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chromogenix Regenlite Transform Treatment</intervention_name>
    <description>Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chromogenix Regenlite Transform Placebo</intervention_name>
    <description>Pulse Dyed Laser - 7mm spot size 0 J/cm2</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are able to give voluntary, written informed consent to participate in&#xD;
             this study and from whom consent has been obtained including HIPAA authorization.&#xD;
&#xD;
          -  Healthy male or non-pregnant female 18-65 years-of-age with a clinical diagnosis of&#xD;
             mild to moderate facial acne vulgaris.&#xD;
&#xD;
          -  Subject must have at least eight and not more than fifty inflammatory facial lesions&#xD;
             (i.e., papules/pustules) and no nodules on the face. For the purposes of study&#xD;
             treatment and evaluation, these lesions should be limited to the facial treatment area&#xD;
             including those present on the nose. Lesions involving the eyes, and scalp should be&#xD;
             excluded from the count.&#xD;
&#xD;
          -  Subject must be in general good health and free from any clinically significant&#xD;
             disease, other than acne, that might interfere with the study evaluations.&#xD;
&#xD;
          -  Female subjects of childbearing potential (excluding women who are surgically&#xD;
             sterilized or postmenopausal for at least 1 year), in addition to having a negative&#xD;
             urine pregnancy test, must be willing to use an acceptable form of birth control&#xD;
             during the study from the day of the first dose administration to 30 days after the&#xD;
             last administration of study drug.&#xD;
&#xD;
          -  Subjects who use make-up must have used the same brands/types of make-up for a minimum&#xD;
             period of 14 days prior to study entry and must agree to use the same make-up&#xD;
             brand/type and frequency of use throughout the study.&#xD;
&#xD;
          -  Subjects must agree not to have any other procedures affecting skin quality&#xD;
             (microdermabrasion, peels, acne treatments, etc.) for the duration of the study.&#xD;
&#xD;
          -  Subjects must understand the study and be able to follow study instructions as well as&#xD;
             attend the required study visits.&#xD;
&#xD;
          -  Subjects who agree to be photographed for research purposes and their identity may not&#xD;
             be concealed in these photographs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whom are pregnant, planning to become pregnant or breastfeeding. A urine&#xD;
             pregnancy test will be done to rule out pregnancy.&#xD;
&#xD;
          -  Subjects of child-bearing potential who are not using an approved method of birth&#xD;
             control (oral contraceptives, IUD, contraceptive implant, barrier methods with&#xD;
             spermicide or abstinence). Females of non-childbearing potential are defined as&#xD;
             post-menopausal (absence of menstrual bleeding for one year), hysterectomy or&#xD;
             bilateral oophorectomy.&#xD;
&#xD;
          -  Subjects who cannot understand or are not willing to comply with the requirements of&#xD;
             the study.&#xD;
&#xD;
          -  Presence of any skin condition on the face that would interfere with the diagnosis or&#xD;
             assessment of acne.&#xD;
&#xD;
          -  Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne.&#xD;
&#xD;
          -  The use within 6 months prior to baseline of oral retinoids (e.g. AccutaneÂ®) or&#xD;
             therapeutic vitamin A supplements of greater than 10,000units/day (multivitamins are&#xD;
             allowed).&#xD;
&#xD;
          -  The use of estrogens or oral contraceptives for less than 3 months prior to baseline.&#xD;
&#xD;
          -  The use within 1 month prior to baseline of:&#xD;
&#xD;
               -  topical retinoids to the face;&#xD;
&#xD;
               -  systemic antibiotics known to have an impact on the severity of facial acne&#xD;
                  (e.g., containing tetracycline and its derivatives, erythromycin and its&#xD;
                  derivatives, sulfamethoxazole, or trimethoprim);&#xD;
&#xD;
               -  systemic corticosteroids (Note: intranasal and inhalational corticosteroids do&#xD;
                  not require a washout and maybe used throughout the trial if the subject is on a&#xD;
                  stable dose).&#xD;
&#xD;
          -  Use within 2 weeks prior to baseline of:&#xD;
&#xD;
               -  topical corticosteroids;&#xD;
&#xD;
               -  topical antibiotics;&#xD;
&#xD;
               -  topical medications for acne (e.g., metronidazole).&#xD;
&#xD;
          -  Subjects with moderate or severe rhinophyma, dense telangiectases (score 3, severe),&#xD;
             or plaque-like facial edema.&#xD;
&#xD;
          -  Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient&#xD;
             severity to require topical or systemic antibiotics.&#xD;
&#xD;
          -  A subject who has used a sauna during the 2 weeks prior to study entry and during the&#xD;
             study.&#xD;
&#xD;
          -  Subjects who have performed wax epilation of the face within 14 days prior to&#xD;
             baseline.&#xD;
&#xD;
          -  A subject with bacterial folliculitis.&#xD;
&#xD;
          -  A subject who consumes excessive alcohol, abuses drugs or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements.&#xD;
&#xD;
          -  Subjects who engage in activities that involve excessive or prolonged exposure to&#xD;
             sunlight or weather extremes, such as wind or cold.&#xD;
&#xD;
          -  A subject who has any clinically significant condition or situation, other than the&#xD;
             condition being studied that, in the opinion of the Investigator, would interfere with&#xD;
             the study evaluations or optimal participation in the study.&#xD;
&#xD;
          -  A subject who has used any topical azelaic acid therapy within 30 days of baseline&#xD;
             visit.&#xD;
&#xD;
          -  Subjects who have participated in an investigational drug study (i.e., subjects have&#xD;
             been treated with an Investigational Drug) within 30 days prior to baseline will be&#xD;
             excluded from study participation. Subjects who are participating in non-treatment&#xD;
             studies such as observational studies or registry studies can be considered for&#xD;
             inclusion.&#xD;
&#xD;
          -  Subjects who have been previously enrolled in this study.&#xD;
&#xD;
          -  Subjects who have had laser therapy (for telangiectasia or other conditions),&#xD;
             electrodessication and phototherapy to the facial area within 180 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Subjects who have had cosmetic procedures (e.g., facials) which may affect the&#xD;
             efficacy and safety profile of the Investigational Product within 14 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Subjects who have had any kind of facial dermabrasion, chemical peel, laser, IPL or&#xD;
             any other treatment that could influence the skin quality in the past 6 months or for&#xD;
             the duration of the study&#xD;
&#xD;
          -  Subjects who do not agree to avoid using tanning beds or intensive exposure to the sun&#xD;
             two weeks prior to each office visit.&#xD;
&#xD;
          -  Subjects who have any known cancer including skin cancers (basal cell carcinoma,&#xD;
             squamous cell carcinoma and melanoma) in the treatment area.&#xD;
&#xD;
          -  Subjects who are currently involved in any injury litigation claims.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 31, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

